341 related articles for article (PubMed ID: 27998711)
21. Translational CNS medicines research.
Palmer AM; Alavijeh MS
Drug Discov Today; 2012 Oct; 17(19-20):1068-78. PubMed ID: 22580061
[TBL] [Abstract][Full Text] [Related]
22. Strategies for delivering therapeutics across the blood-brain barrier.
Terstappen GC; Meyer AH; Bell RD; Zhang W
Nat Rev Drug Discov; 2021 May; 20(5):362-383. PubMed ID: 33649582
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges.
Geerts H; Wikswo J; van der Graaf PH; Bai JPF; Gaiteri C; Bennett D; Swalley SE; Schuck E; Kaddurah-Daouk R; Tsaioun K; Pelleymounter M
CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):5-20. PubMed ID: 31674729
[TBL] [Abstract][Full Text] [Related]
24. Targeting neuronal function for CNS drug discovery.
Hempel CM; Werley CA; Dempsey GT; Gerber DJ
Drug Discov Today Technol; 2017 Mar; 23():17-25. PubMed ID: 28647082
[TBL] [Abstract][Full Text] [Related]
25. Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective.
Butlen-Ducuing F; Pétavy F; Guizzaro L; Zienowicz M; Haas M; Alteri E; Salmonson T; Corruble E
Nat Rev Drug Discov; 2016 Nov; 15(12):813-814. PubMed ID: 27895328
[No Abstract] [Full Text] [Related]
26. Animal models of CNS disorders.
McGonigle P
Biochem Pharmacol; 2014 Jan; 87(1):140-9. PubMed ID: 23811310
[TBL] [Abstract][Full Text] [Related]
27. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
28. Role of Academic Drug Discovery in the Quest for New CNS Therapeutics.
Yokley BH; Hartman M; Slusher BS
ACS Chem Neurosci; 2017 Mar; 8(3):429-431. PubMed ID: 28195461
[TBL] [Abstract][Full Text] [Related]
29. Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review.
Sahu JK; Mishra AK
Curr Mol Pharmacol; 2018; 11(4):270-278. PubMed ID: 30129422
[TBL] [Abstract][Full Text] [Related]
30. Adult neurogenesis pharmacology in neurological diseases and disorders.
Taupin P
Expert Rev Neurother; 2008 Feb; 8(2):311-20. PubMed ID: 18271715
[TBL] [Abstract][Full Text] [Related]
31. Clinical Trials in CNS--SMi's Seventh Annual Conference. 25-26 November 2008, London, UK.
Sherwood D
IDrugs; 2009 Feb; 12(2):84-6. PubMed ID: 19204879
[No Abstract] [Full Text] [Related]
32. The effects of Chinese medicines on cAMP/PKA signaling in central nervous system dysfunction.
Li L; Fan X; Zhang XT; Yue SQ; Sun ZY; Zhu JQ; Zhang JH; Gao XM; Zhang H
Brain Res Bull; 2017 Jun; 132():109-117. PubMed ID: 28438669
[TBL] [Abstract][Full Text] [Related]
33. A role for fMRI in optimizing CNS drug development.
Borsook D; Becerra L; Hargreaves R
Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
[TBL] [Abstract][Full Text] [Related]
34. Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases.
Bai X; Fu RJ; Zhang S; Yue SJ; Chen YY; Xu DQ; Tang YP
Biomed Pharmacother; 2021 Jul; 139():111551. PubMed ID: 33865016
[TBL] [Abstract][Full Text] [Related]
35. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
Al-Shamahi A; Kirkham K; Hookes L
IDrugs; 2009 Dec; 12(12):734-7. PubMed ID: 19943211
[TBL] [Abstract][Full Text] [Related]
36. Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies.
Khambhla E; Shah V; Baviskar K
Curr Pharm Des; 2016; 22(19):2913-22. PubMed ID: 27033697
[TBL] [Abstract][Full Text] [Related]
37. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles.
Blazer LL; Neubig RR
Neuropsychopharmacology; 2009 Jan; 34(1):126-41. PubMed ID: 18800065
[TBL] [Abstract][Full Text] [Related]
38. Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning.
Morofuji Y; Nakagawa S
Curr Pharm Des; 2020; 26(13):1466-1485. PubMed ID: 32091330
[TBL] [Abstract][Full Text] [Related]
39. Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide.
Banks WA; Greig NH
Future Med Chem; 2019 Mar; 11(6):489-493. PubMed ID: 30912980
[No Abstract] [Full Text] [Related]
40. Antibody therapies in CNS diseases.
Freskgård PO; Urich E
Neuropharmacology; 2017 Jul; 120():38-55. PubMed ID: 26972827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
